Bausch + Lomb announced an affiliate has acquired Trukera Medical from its private equity owner, AccelMed Partners, and other shareholders. The tuck-in acquisition will help expand Bausch + Lomb’s surgical presence in the United States and contribute to its leading position in dry eye, the company said in a press release. 

Trukera Medical, a US-based privately held ophthalmic medical diagnostic company, commercializes ScoutPro, a point-of-care portable device for precisely measuring osmolarity, or the salt content of a person’s tears. Hyperosmolarity, a condition not detectable by slit lamp examination, is a leading indicator and central etiology of asymptomatic dry eye disease and ocular surface disease, which can negatively affect corneal, cataract and refractive surgery outcomes if not treated effectively prior to the procedure.

“ScoutPro has already become a valuable preoperative diagnostic tool for many US surgeons, and with our scale we believe it can have an even greater impact,” Luc Bonnefoy, president, Surgical, Bausch + Lomb said in the press release.